Press release
Duchenne Muscular Dystrophy Clinical Trial Updates 2024 | FDA Approvals, Therapies in Focus | Vyondys 53 (Golodirsen), Emflaza, Exondys 51, Translarna, Amondys 45, Viltepso, PF-06939926, Vamorolone
Duchenne Muscular Dystrophy Pipeline Insight
As per DelveInsight's assessment, globally, about 75+ key pharma and biotech companies are working on 75+ pipeline drugs in the Duchenne Muscular Dystrophy (DMD) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Duchenne Muscular Dystrophy (DMD) Pipeline Insight, 2024 [https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Duchenne Muscular Dystrophy Market.
The Duchenne Muscular Dystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Duchenne Muscular Dystrophy Pipeline Analysis
The report provides insights into:
* The report provides detailed insights into the emerging therapies for the treatment of Duchenne Muscular Dystrophy and the aggregate therapies developed by major pharma companies.
* It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
* It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Duchenne Muscular Dystrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
DelveInsight's Report covers around 75+ products under different phases of clinical development like -
* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Route of Administration - The Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROA, such as -
* Oral
* Intravenous
* Subcutaneous
Molecule Type - Products have been categorized under various Molecule types, such as
* Small molecule
* Cell Therapy
* Peptides
* Polymer
* Small molecule
* Gene therapy
Duchenne Muscular Dystrophy Emerging Therapies - Mechanisms of Action (MOA) Types
* Dipeptidyl peptidase I inhibitors
* Peroxisome proliferator-activated receptor delta modulators
* Cell replacements
* Dystrophin expression stimulants
* Connective tissue growth factor inhibitors
* Dystrophin replacements
* Immunostimulants
* Gene modulators
* Dystrophin expression modulators
Learn How the Ongoing Clinical & Commercial Activities will Affect the Duchenne Muscular Dystrophy Therapeutic Segment @ https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight [https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Duchenne Muscular Dystrophy Therapeutics Landscape [https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
There are approx. 75+ key companies developing therapies for Duchenne Muscular Dystrophy. Currently, Roche is leading the therapeutics market with its Duchenne Muscular Dystrophy drug candidates in the most advanced stage of clinical development among all the major players in the segment.
Leading Companies in the Duchenne Muscular Dystrophy Therapeutics Market [https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] Include:
* Santhera Pharmaceuticals
* Sarepta Therapeutics
* Italfarmaco
* Wave Life Sciences Ltd
* FibroGen
* Edgewise Therapeutics
* Fordadistrogene movaparvovec
* Daiichi Sankyo
* Sarepta Therapeutics, Inc.
* ENCell
* Taiho Pharmaceutical
* Solid Biosciences
* Capricor
* Nippon Shinyaku
* Hansa Biopharma
* And Many Others
Duchenne Muscular Dystrophy Drugs Covered in the Report Include:
* Vamorolone: Santhera
* Givinostat: Italfarmaco
* Pamrevlumab: Fibrogen
* WVE N531: WaVe lifeSciences
* CRISPR/Cas9 gene editing therapy: Vertex Pharmaceuticals
* MA-0211: Mitobridge
* BLS-M22: Bioleaders Corporation
* CAP 1002: Capricor
* DS-5141: Daiichi Sankyo
* TAS-205: Taiho Pharmaceutical
* And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight [https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Duchenne Muscular Dystrophy Current Treatment Patterns
4. Duchenne Muscular Dystrophy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Duchenne Muscular Dystrophy Late Stage Products (Phase-III)
7. Duchenne Muscular Dystrophy Mid-Stage Products (Phase-II)
8. Duchenne Muscular Dystrophy Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Duchenne Muscular Dystrophy Discontinued Products
13. Duchenne Muscular Dystrophy Product Profiles
14. Key Companies in the Duchenne Muscular Dystrophy Market
15. Key Products in the Duchenne Muscular Dystrophy Therapeutics Segment
16. Dormant and Discontinued Products
17. Duchenne Muscular Dystrophy Unmet Needs
18. Duchenne Muscular Dystrophy Future Perspectives
19. Duchenne Muscular Dystrophy Analyst Review
20. Appendix
21. Report Methodology
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=duchenne-muscular-dystrophy-clinical-trial-updates-2024-fda-approvals-therapies-in-focus-vyondys-53-golodirsen-emflaza-exondys-51-translarna-amondys-45-viltepso-pf06939926-vamorolone]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Duchenne Muscular Dystrophy Clinical Trial Updates 2024 | FDA Approvals, Therapies in Focus | Vyondys 53 (Golodirsen), Emflaza, Exondys 51, Translarna, Amondys 45, Viltepso, PF-06939926, Vamorolone here
News-ID: 3473962 • Views: …
More Releases from ABNewswire
Atypical Hemolytic Uremic Syndrome Market Positioned for Accelerated Development …
The Key Atypical Hemolytic Uremic Syndrome Companies in the market include - Alexion Pharmaceuticals, Hoffmann-La Roche, Novartis, NovelMed Therapeutics, and others.
The Atypical Hemolytic Uremic Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Atypical Hemolytic Uremic Syndrome pipeline products will significantly revolutionize the Atypical Hemolytic Uremic Syndrome market dynamics.
DelveInsight's "Atypical Hemolytic Uremic Syndrome Market Insights, Epidemiology, and…
"Apres Surf" - A Captivating New Documentary Celebrating Surf Culture and the Mo …
The 16-minute documentary will premiere in Florida at the Jollywood Film Festival in Orlando on November 12th and 13th, 2025, at the Marriott Renaissance Airport Hotel.
Orlando, FL - October 27th, 2025 - Award-winning filmmaker George Ellis, MD [https://filmfreeway.com/GeorgeEllis], is proud to announce the gripping new documentary, "Apres Surf [https://filmfreeway.com/ApresSurf]," available for a special viewing at the Jollywood Film Festival [https://www.jollywoodfilmfestival.com/] in Orlando on November 12th and 13th, 2025, at the…
FreeCast Adds Local Broadcast Channels Erie News Now, WENY News
A deal with Lilly Broadcasting brings two channels from New York and Pennsylvania to FreeCast's free streaming channels.
FreeCast is announcing a new agreement with Lilly Broadcasting, expanding its offering of local channels with free versions of two broadcast TV stations. Erie News Now and WENY News are both now available to FreeCast users at no additional cost. As streaming video overtakes linear television and smart televisions become the norm, there's…
Medical Clinic Documents Significant Recovery Rates in Peripheral Neuropathy Pat …
Los Angeles medical facility documents significant recovery rates in peripheral neuropathy patients using EBOO blood oxygenation technology, showing measurable improvements in sensation restoration and symptom relief.
LOS ANGELES, CA - Ebo2 Therapy and Wellness | Los Angeles [http://index.businessinsurance.com/businessinsurance/article/abnewswire-2025-8-21-local-eboo-clinic-achieves-95-patient-satisfaction-rate-making-specialized-iv-therapy-near-me-more-accessible-than-ever] has documented notable recovery outcomes in patients suffering from peripheral neuropathy through specialized blood oxygenation treatments. The medical facility's recent patient data reveals substantial improvements in sensation restoration and symptom management using Extracorporeal…
More Releases for Duchenne
Duchenne Muscular Dystrophy: Core Growth Enabler in the Rising Prevalence Of Chr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Duchenne Muscular Dystrophy Industry Market Size Be by 2025?
The market size for Duchenne Muscular Dystrophy has shown significant expansion recently, burgeoning from $1.16 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The impressive growth in the…
Emerging Trends Influencing The Growth Of The Duchenne Muscular Dystrophy (DMD) …
The Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Expected to Be by 2034?
In recent times, the market size for Duchenne Muscular Dystrophy (DMD) therapeutics has seen a significant…
Shaping the Duchenne Muscular Dystrophy (DMD) Therapeutics Market in 2025: Bit B …
How Big Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Expected to Be, and What Will Its Growth Rate Be?
The Duchenne muscular dystrophy (DMD) therapeutics market will grow from $11.95 billion in 2024 to $16.45 billion in 2025, at a CAGR of 37.6%. The growth is attributed to the increasing prevalence of Duchenne muscular dystrophy, rising awareness of treatment options, healthcare spending, and government initiatives.
The Duchenne muscular dystrophy (DMD) therapeutics…
Duchenne Muscular Dystrophy Pipeline Outlook Report 2024
DelveInsight's, "Duchenne Muscular Dystrophy Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Duchenne Muscular Dystrophy pipeline landscape. It covers the Duchenne Muscular Dystrophy pipeline drug profiles, including Duchenne Muscular Dystrophy clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
…
Duchenne Muscular Dystrophy Treatmcent Market
Global Duchenne Muscular Dystrophy Treatmcent Market Set for Robust Growth During Forecast Period
The global Duchenne Muscular Dystrophy Treatment Market is poised to witness significant growth at a high Compound Annual Growth Rate (CAGR) during the forecast period of 2023 to 2030. Duchenne muscular dystrophy (DMD) stands as a genetic disorder marked by progressive muscle degeneration and weakness, with therapeutics aimed at addressing the absence of dystrophin, a crucial protein in…
Duchenne Muscular Dystrophy (DMD) Drugs Market Report
As per the research conducted by GME, the Duchenne Muscular Dystrophy (DMD) Drugs Market will grow with a CAGR value of 41.3 percent by 2026. The global market for Duchenne muscular dystrophy is foreseen to grow due to accelerated research and development activities, expanded patient awareness for effective treatments, and the launch of new medications Moreover, the disease's increasing prominence is likely to drive the global duchenne muscular dystrophy market…
